The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 1 CME credit.
Read More
The coronavirus can penetrate the brain, causing delirium, psychosis, and persistent cognitive problems in patients with COVID-19.Lithium has antiviral effects, but its role in COVID-19 is undetermined. 1 in 3 patients with bipolar disorder are excellent lithium responders.Delusional disorder requires more than medication. Antipsychotics have limited efficacy here, and pimozide...
Read More
Pandemics create a long list of psychosocial stressors, but COVID-19 also has direct effects on the CNS. Neuropsychiatric syndromes can develop after the respiratory illness resolves. Paul Riordan reviews the cardinal symptoms to look for after a COVID infection.
Read More
Some patients respond so well to lithium that they rarely need other interventions. Janusz Rybakowski sums up what we know about the optimal lithium responder, how to use this underutilized medication, and what lithium’s antiviral properties mean in the era of COVID-19.
Read More
Delusional disorder may be in the psychotic chapter, but it doesn’t respond to antipsychotics like we’d expect. Joseph Pierre reviews how to use them, which ones to avoid, and how to enhance your therapeutic relationship with this population.
Read More
Carbamazepine or valproic acid? Both have been used to augment lithium for decades, but which one works best? A new trial tests them head-to-head.
Read More
On July 13, 2020, SAMHSA modernized the law to allow disclosure without patient consent during emergencies that result from a natural disaster. COVID-19 is included alongside hurricanes and floods in the list, though the opioid crisis is not.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
